<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>INFECTION IMMUNITY, Aug. 2008, p. 3577&#226;&#8364;&#8220;3586                                                                                       Vol. 76,  8 <br /> 0019-9567/08/$08.00&#226;&#171;&#185;0 doi:10.1128/IAI.00269-08 <br /> Copyright &#194;&#169; 2008, American Society Microbiology. Rights Reserved. <br />  <br />  <br />  <br />      Rat Pneumonia Soft-Tissue Infection Models Study                    Acinetobacter baumannii Biology&#228;&#338;&#164; <br />              Thomas  Russo,1,2,3,4,5* Janet M. Beanan,2,4 Ruth Olson,2,4 Ulrike MacDonald,2,4 <br />                  Nicole R. Luke,3,4,5 Steven R. Gill,4,5,6 Anthony  Campagnari3,4,5 <br />       Veterans Administration Western New York Healthcare 1 Department Medicine,2 Department Microbiology,3 <br />           Witebsky Center Microbial Pathogenesis,4 Center Excellence Bioinformatics Life Sciences,5              Department Oral Biology,6 University Buffalo-State University New York, Buffalo, New York 14214 <br />                                               Received 26 February 2008/Accepted 28 2008 <br />  <br />              Acinetobacter baumannii bacterial pathogen increasing medical importance. Little known           mechanisms pathogenesis, safe reliable agents predictable activity  baumannii           presently nonexistent. availability relevant animal infection models facilitate study Acineto- <br />           bacter biology. report tested hypothesis rat pneumonia soft-tissue infection models <br />           laboratory previously used studies extraintestinal pathogenic Escherichia coli clinically <br />           relevant  baumannii. Advantages models previously described models animals <br />           rendered neutropenic did receive porcine mucin bacterial challenge. Using  <br />           baumannii model pathogen 307-0294 challenge pathogen, pneumonia model demonstrated           features infection critical clinically relevant model:  bacterial growth/clearance,           ensuing host inflammatory response, acute lung injury,  following progressive bacterial proliferation, <br />           death respiratory failure. able demonstrate growth 307-0294 soft-tissue <br />           infection model. tested hypothesis soft-tissue infection model used discriminate <br />           inherent differences virulence various  baumannii clinical isolates. ability  <br />           baumannii grow cleared model dependent challenge strain. hypothesized <br />           complement important host factor protecting  baumannii infection vivo. support <br />           hypothesis observation serum sensitivity various  baumannii clinical isolates           vitro roughly paralleled growth/clearance soft-tissue infection model vivo. Lastly hypothesized <br />           soft-tissue infection model serve efficient screening mechanism identifying gene <br />           essentiality drug discovery. Random mutants 307-0294 initially screened lack growth           human ascites vitro. Selected mutants subsequently used challenge soft-tissue infection model <br />           determine disrupted gene essential growth vivo. Using approach, able           successfully identify number genes essential growth 307-0294 vivo. summary, models <br />           clinically relevant used study innate virulence various Acinetobacter clinical isolates           assess potential virulence factors, vaccine candidates, drug targets vivo used           pharmacokinetic chemotherapeutic investigations. <br />  <br />  <br />    Acinetobacter species highly prevalent environment                urinary tract; intravenous devices; surgical sites; decubitus cultured moist skin healthy humans,                   diabetic ulcers favored sites infection. Mortality rates  <br /> increased colonization skin respiratory gastrointestinal             sociated Acinetobacter infection range 19 54% (16). <br /> tracts occurs individuals long-term care hospital facili-             Interestingly,  baumannii reported uncommonly <br /> ties. overwhelming majority infections described                cause severe community-acquired pneumonia, usually abnor- <br /> cently acquired mainly hospitals, lesser degree               mal hosts (e.g., alcoholics), preponderance cases  long-term care facilities, rarely community.               ported warm humid geographic locales (1, 2, 6). Fur- <br /> Acinetobacter baumannii accounts 1 3% hospital-ac-                    ther, importance Acinetobacter infections war-related <br /> quired infections 2 10% infections intensive care units            injuries established.  baumannii common <br /> (14, 33, 49). sporadic epidemic infections occur, usually              gram-negative bacillus recovered traumatic injuries week hospitalization (3, 13, 14, 19, 51). Impor- <br />                                                                                 lower extremities Vietnam War (48). recently tantly, incidence Acinetobacter infection increasing world- <br />                                                                                 new series infections  baumannii reported wide (13, 16, 33). respiratory tract, particularly ventilated <br />                                                                                 U.S. service members injured Iraq, Kuwait, Afghanistan (5, <br /> patients (6.9% hospital-acquired pneumonias 2003 based                                                                                 10, 11, 18, 44). majority patients sustained traumatic inju- <br /> National Nosocomial Infection Surveillance data);                                                                                 ries, infectious syndromes included soft-tissue infection, os- <br />                                                                                 teomyelitis, pneumonia, bacteremia (30). Lastly, Acineto- <br />   * Corresponding author. Mailing address: Department Medicine,              bacter emerged important pathogen survivors Division Infectious Diseases, University Buffalo, 3435 Main St.,          Asian tsunami 2004 (15, 24). summary, changing epide- <br /> Biomedical Research Building (Room 141), Buffalo, NY 14214. <br />                                                                                 miology incidence infections Acinetobacter establish <br /> Phone: (716) 829-2674. Fax: (716) 829-3889. E-mail: trusso@acsu <br /> .buffalo.edu.                                                                   pathogen increasing medical importance. <br />   &#228;&#338;&#164; <br />     Published ahead print 9 June 2008.                                       centers incidence infections highly <br />  <br />                                                                          3577 <br />  3578       RUSSO ET AL.                                                                                                                               INFECT. IMMUN. <br />  <br />  <br /> antibiotic-resistant strains making treatment challenging (17,                   oxygen (FiO2) 98% administered, midline incision 29, 32, 45, 47, 50). Particularly problematic panresistant                      peritoneum thoracic cavity. arterial blood <span id='am-5' about='obo:IMR_0001720' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-6' property="oboInOwl:hasDbXref" content="MeSH:D005740" datatype="xsd:string"></span><span id='am-7' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-8' property="obo:IAO_0000115" content="The vapor state of matter; nonelastic fluids in which the molecules are in free movement and their mean positions far apart. Gases tend to expand indefinitely, to diffuse and mix readily with other gases, to have definite relations of volume, temperature, and pressure, and to condense or liquefy at low temperatures or under sufficient pressure." datatype="xsd:string"></span><span id='am-9' property="oboInOwl:id" content="IMR:0001720" datatype="xsd:string"></span><span id='am-10' property="rdfs:label" content="gas" datatype="xsd:string"></span>gas</span> sample                                                                                     obtained descending aorta 1-ml heparinized syringe. pulmo- <br /> strains. 1999 New York City outbreak, 12%  bau-                           nary vasculature flushed residual blood injecting right ventricle mannii isolates resistant standard antimicrobials                       20 ml 1&#226;&#171;&#187; Hanks&#226;&#8364;&#8482; balanced salt solution plus 7.5% NaHCO3 (pH 7.2) using (23). rates higher outside United States. Safe                        22-gauge needle.  bronchoalveolar lavage (BAL) performed 15 ml <br /> reliable agents predictable activity  baumannii                      normal saline (37&#194;&#176;C) administered lungs gravity                                                                                     tracheal cannula. recovered BAL fluid (BALF) kept ice. 500-&#226;?&#174;l presently nonexistent. <br />                                                                                     aliquot recovered BALF removed subsequent measurement bac- <br />    need increased understanding Acinetobacter                         terial CFU. remaining BALF centrifuged 1,500 &#226;&#171;&#187; g pellet pathogenesis, identification virulence factors, iden-                    cellular fraction. supernatant removed frozen &#226;&#171;&#186;80&#194;&#176;C cyto- <br /> tification testing vaccine candidates new antimicro-                     kine/chemokine assessments  subsequent section pulmonary inflamma- <br /> bial targets pressing (28, 46). order                       tory response). cellular fraction resuspended 3 ml ice-cold 1&#226;&#171;&#187; PBS, <br />                                                                                     carefully layered 2 ml cold-filtered 2% bovine serum albumin 1&#226;&#171;&#187; PBS, <br /> accomplish goals critical identify/develop relevant                  centrifuged 150 &#226;&#171;&#187; g, resuspended 4 ml ice-cold 1&#226;&#171;&#187; PBS. Lastly, animal models infection. <span id='am-15' about='oboInOwl:date' typeof='owl:Thing'>date</span>, Acinetobacter                         lungs removed kept 4&#194;&#176;C. <br /> used variety animal models, including murine (21, 22,                            Assessment bacterial growth/clearance. Intact, excised post-BAL lungs <br /> 25, 26, 31, 36) guinea pig (4) pneumonia models, rat                          weighed suspended normal saline total weight 10 g (assumed <br /> thigh infection model (27), rabbit endocarditis model                         equate 10 ml). addition saline served vehicle homogenization <br />                                                                                     generate constant volume titers easily calcu- <br /> (35).  clinical relevance suitability                      lated. Lungs homogenized ice  bursts 3-s duration  <br /> models vary depending hypothesis tested.                       using Polytron PT-2000 homogenizer (Brinkman Instruments, Westbury, NY). <br /> report tested hypothesis rat pneumonia                          Total Acinetobacter titers determined enumerating combined bacteria soft-tissue infection models laboratory previously                     BALF plus post-BAL lung tissue described previously (41). <br />                                                                                        (ii) Assessment pulmonary host response.   Measurement rat <br /> used studies extraintestinal pathogenic Escherichia coli <br />                                                                                     TNF-&#226;?&#163;, 1&#226;?&#164;, CINC-1 levels BALF. Sandwich enzyme-linked immu- clinically relevant studying  baumannii infection.                       nosorbent assays utilizing commercial antibodies standards (R<span id='am-16' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-17' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-18' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-19' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span><span id='am-22' property="rdfs:label" content="AMP" datatype="xsd:string"></span>amp</span>;D Systems tested hypothesis soft-tissue infection                        , Minneapolis, MN) employed measuring levels rat tumor necrosis <br /> model used discriminate inherent                            factor alpha (TNF-&#226;?&#163;), interleukin-1&#226;?&#164;  1&#226;?&#164;), cytokine-induced neutrophil <br /> differences virulence various  baumannii clinical iso-                      chemoattractant 1 (CINC-1) described previously (40). <br />                                                                                        (b) Measurement BALF cell counts. 50-&#226;?&#174;l aliquot diluted 1:200 lates. hypothesized complement important                         Isoton II solution (Beckman Coulter), leukocyte concentration host factor protecting  baumannii infection vivo.                   determined using Multisizer 3 Coulter Counter (Beckman Coulter). cy- <br /> Lastly hypothesized soft-tissue infection model                         toslide prepared diluting cells final concentration 5 &#226;&#171;&#187; 104 leuko- serve efficient screening mechanism establish-                      cytes, using Cytospin 3 cytocentrifuge (Shandon, Pittsburgh, PA), staining                                                                                     Diff-Quik reagents (Baxter, Miami, FL), examination light microscopy <br /> ing gene essentiality drug discovery. results suggest <br />                                                                                     (Nikon Microscope ECLIPSE 80i; Nikon Instruments , Melville, NY). models suited clinically relevant                          (iii) Assessment lung injury. Arterial blood oxygenation measured <br /> testing answering variety questions related infec-                      (ABL5; Radiometer America, Westlake, OH) reported arterial partial <br /> tions  baumannii.                                                          pressure oxygen divided fraction inspired oxygen (PaO2/FiO2 ratio). <br />                                                                                     Albumin concentrations cell-free BAL measured enzyme-linked im- <br />                                                                                     munosorbent assay using polyclonal rabbit anti-mouse albumin antibody  gift <br />                         MATERIALS METHODS                                       Daniel Remick, University Michigan, Ann Arbor, MI) horseradish <br />    Bacterial strains media.  baumannii strain 307-0294 (blood isolate,        peroxidase-labeled goat anti-rabbit immunoglobulin (Pharmingen, San Diego, <br /> sequence type 15 [ST15], clonal group 1 based work Ecker et al. [12])     CA) (9). Rat albumin (Sigma, St. Louis, MO) used standard. isolated patient hospitalized Erie County Medical Center, Buffalo,       Rat soft-tissue infection model. Long-Evans rats (200 250 g) anesthe- <br /> NY.  baumannii strains 853 (OIFC031) (blood isolate, ST11, clonal group II),      tized described pneumonia model. subcutaneous space created <br /> 855 (OIFC075) (axillary isolate, ST14, clonal group III), 900 (OIFC111) (peri-      rat injecting 50 ml air subcutaneously injecting <br /> neal isolate, ST19, clonal group undetermined), 979 (OIFC327) (environ-         mixture sterile vegetable oil (975 &#226;?&#174;l) croton oil (25 &#226;?&#174;l) space <br /> mental isolate, ST24, clonal group undetermined) isolated infected        created. 7 days resulted encapsulated &#226;&#8364;&#339;pouch&#226;&#8364;? filled military personnel serving Iraq Afghanistan (kindly provided David        exudative fluid (pouch fluid), mimicking subcutaneous abscess. model <br /> Craft Paul Scott Walter Reed Army Medical Center). strains      characterized (7, 8). dynamic model, evidenced fact <br /> grown Luria-Bertani (LB) medium unless stated main-           neutrophils migrate pouch response appropriate stimuli. <br /> tained &#226;&#171;&#186;80&#194;&#176;C 50% LB broth 50% glycerol. Ascites plates consisted       Bacteria introduced pouch, pouch fluid easily removed <br /> 80% human ascites 20% water. milliliters water 15 g       time, enabling study microbial host responses. day 8, <br /> Bacto agar autoclaved cooled 45&#194;&#176;C, 800 ml ascites kanamycin      approximately 5 &#226;&#171;&#187; 106 CFU  baumannii strain assessed (40-&#226;?&#174;g/ml final concentration) added, plates poured. quanti-       injected pouches anesthetized animals, resulting estimated starting <br /> tative growth curves ascites, 100% human ascites utilized.                   pouch concentrations 1 &#226;&#171;&#187; 105 2 &#226;&#171;&#187; 105 CFU/ml. 1 minute    Rat pneumonia model. rat pneumonia soft-tissue infection model           bacteria injected pouch, 0.5 ml pouch fluid removed animal studies reviewed approved University Buffalo          measure actual starting bacterial titer. Fluid aliquots (0.5 ml) subse- <br /> Veterans Administration Institutional Animal Care Committee. established         quently obtained anesthetized animals 3, 6, 24, 48 h initial <br /> rat (Long-Evans) model studying pulmonary damage used reported           bacterial challenge, bacterial titers determined enumerating bacte- <br /> previously (39, 41). brief, Long-Evans rats (250 300 g) anesthetized     rial CFU pouch fluid serial 10-fold dilutions 1&#226;&#171;&#187; PBS. 3.5% halothane 100% oxygen unconscious maintained            Serum bactericidal assay. Complement-mediated bactericidal assays  <br /> 3.5% halothane. trachea exposed surgically, 4  piece 1-0 silk   formed measuring change bacterial titer time presence slipped trachea facilitate instillation inoculum.       90% active inactive (heated 56&#194;&#176;C 30 min) human serum. input <br /> animals suspended supine position 60&#194;&#176;-incline board. Pulmonary       bacterial titer approximately 1 &#226;&#171;&#187; 105 CFU utilized, titers instillation bacteria prepared 1&#226;&#171;&#187; phosphate-buffered saline (PBS) (pH 7.4)    measured 0, 1, 2, 3 h described previously (38, 43). introduced intratracheally (1.2 ml/kg body weight) 1-ml syringe       Transposon mutagenesis screen lack growth ascites plates. <br /> 26-gauge needle, incision closed surgical staples. Animals    Electrocompetent cells generated growing AB307-0294 Mueller-Hinton <br /> sacrificed 3, 6, 24, 48, 72, 168 h postinoculation assessments        (MH) broth A600 0.4. milliliters cells washed bacterial growth/clearance, pulmonary inflammatory response, lung        1 ml ice-cold sterile milli-Q-filtered <span id='am-23' about='obo:IMR_0200357' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-24' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-25' property="oboInOwl:id" content="IMR:0200357" datatype="xsd:string"></span><span id='am-26' property="rdfs:label" content="H2O" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:hasDbXref" content="KEGG:C00001" datatype="xsd:string"></span>H2O</span> (Millipore, Billerica, MA), followed jury. harvest, halothane anesthesia performed, fraction inspired        washes 10% ice-cold, sterile glycerol. wash, cells  VOL. 76, 2008                                                                                                          BAUMANNII BIOLOGY               3579 <br />  <br />  <br />  <br />  <br />                                                                                          FIG. 2. Survival rats pneumonia model post-challenge <br />                                                                                       different titers  baumannii strain 307-0294. Rats chal- <br />   FIG. 1. Growth/clearance different titers  baumannii strain                 lenged 7.0 &#226;&#171;&#187; 106 (n &#226;&#171;&#189; 18), 5.8 &#226;&#171;&#187; 107 (n &#226;&#171;&#189; 19), 3.5 &#226;&#171;&#187; 108 (n &#226;&#171;&#189; 19), <br /> 307-0294 rat pneumonia model. Rats challenged 7.0 &#226;&#171;&#187;                  4.3 &#226;&#171;&#187; 108 (n &#226;&#171;&#189; 18), 7.7 &#226;&#171;&#187; 109 (n &#226;&#171;&#189; 18) CFU 307-0294 10 , 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU 307-0294 <br />   6                                                                                   intratracheal instillation, survival recorded. trend <br /> (blood isolate, ST15, clonal group 1) intratracheal instillation,              increased survival rats challenged 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 <br /> total lung bacterial titers determined 0, 3, 6, 24, 48, 72,               CFU compared rats challenged 7.7 &#226;&#171;&#187; 109 CFU (&amp;, P &#226;&#171;&#189; 0.03). <br /> 168 h. Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 3 challenge titer time point. <br />  <br />                                                                                       community-acquired nosocomial pneumonia.  <br /> resuspended 75 &#226;?&#174;l used immediately stored &#226;&#171;&#186;80&#194;&#176;C prior use.     tested hypothesis immunocompetent rat pneu- <br /> EZ-Tn5&#226;&#172;?kan-2&#226;&#172;&#381;Tnp Transposome (60 ng 3 &#226;?&#174;l) (Epicentre Biotechnologies; <br />                                                                                       monia model laboratory previously used stud- <br /> catalog  TSM99K2; Madison, WI) electroporated 75 &#226;?&#174;l electrocompe- <br /> tent AB307 (Bio-Rad Gene Pulser; 25 mF/2.5 kV/200 &#226;?&#8364;) using 0.2-cm-gap,             ies extraintestinal pathogenic E. coli clinically relevant <br /> ice-cold EPchamber (Bio-Rad Laboratories, Hercules, CA). Immediately elec-       baumannii (39&#226;&#8364;&#8220;42). pertinent features gram- <br /> troporation cells resuspended S.O.C. medium (Invitrogen, Carlsbad, CA)        negative bacterial pneumonia evaluated:  bacte- grown 37&#194;&#176;C 1 h. Aliquots plated MH plates supplemented        rial growth  clearance), ensuing host inflammatory  kanamycin (40 &#226;?&#174;g/ml), isolated colonies purified  <br /> dium. 307 mutants (presumably 307-0294::Tn5&#226;&#172;?kan-2&#226;&#172;&#381;) subsequently <br />                                                                                       sponse, acute lung injury, death respiratory failure <br /> gridded ascites-kanamycin plates. 307-0294 mutants confirmed        following progressive bacterial proliferation. minimal growth ascites-kanamycin plates numbered consec-          Bacterial growth/clearance. Rats underwent intratracheal <br /> utively stored &#226;&#171;&#186;80&#194;&#176;C.                                                          challenge various titers (7.0 &#226;&#171;&#187; 106 7.7 &#226;&#171;&#187; 109 CFU)    DNA sequencing analysis. location transposon insertion                                                                                        baumannii strain 307-0294 (blood isolate, ST15, clonal <br /> mutant derivatives 307-0294 determined chromosomal sequencing. <br /> Chromosomal DNA prepared 307 mutants using              group 1) determine growth clearance occurred Qiagen DNeasy tissue kit (Qiagen, Valencia, CA) following protocol            vivo pneumonia model 7 days (Fig. 1). Overall, <br /> gram-negative bacteria. UV spectroscopy used determine concentrations.         growth/clearance roughly correlated magnitude DNA used immediately frozen &#226;&#171;&#186;20&#194;&#176;C. Cycle sequencing                 challenge inoculum. highest challenge titer (7.7 &#226;&#171;&#187; 109 <br /> formed EZ-Tn5&#226;&#172;?kan-2&#226;&#172;&#381; Transposon (Epicentre Biotechnologies) using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), follow- <br />                                                                                       CFU) net growth occurred 48 h, ing protocol sequencing genomic DNA. KAN-2 FP-1 forward primer            highest challenge titers (3.5 &#226;&#171;&#187; 108 4.3 &#226;&#171;&#187; 108 CFU) net <br /> included transposon kit used. Cycle sequencing performed            growth occurred 24 h.  72 h net <br /> 20-&#226;?&#174;l reaction mixtures following protocol: 96&#194;&#176;C 5 min, 96&#194;&#176;C 30 s,   clearance occurred challenge titers. day 7, 50&#194;&#176;C 10 s, 60&#194;&#176;C 4 min (40 cycles)/4&#194;&#176;C, ramping 1&#194;&#176;C/s. DNA <br />                                                                                       clearance occurred challenge titers, complete. precipitated adding 30 ml 80% isopropanol reaction mixture. <br /> Reaction mixtures allowed stand dark 15 min               Taken  data support contention  <br /> centrifuged 15 min 2,097 &#226;&#171;&#187; g 4&#194;&#176;C 5415 R refrigerated centrifuge        baumannii able survive grow rat pneumonia <br /> (Eppendorf). Supernatant removed, 70% ethanol added               model dependent challenge inoculum. <br /> reaction mixture. Reaction mixtures centrifuged 15 min 2,097 &#226;&#171;&#187; g       Survival. Rats underwent intratracheal challenge vari- 4&#194;&#176;C. Supernatants removed, reaction mixtures air dried 10 <br /> min dark. 20 ml HiDi formamide (Applied Biosystems)                                                                                       ous titers (7.0 &#226;&#171;&#187; 106 7.7 &#226;&#171;&#187; 109 CFU) 307-0294 deter- <br /> added reaction mixture. vortexed 15 s. Sanger sequencing         mortality occurred vivo pneumonia model performed 3130xl Genetic Analyzer DNA sequencer (Applied Biosys-             7 days (Fig. 2). deaths occurred challenge tems) according manufacturer&#226;&#8364;&#8482;s protocol. Sequence comparisons             7.0 &#226;&#171;&#187; 106 (n &#226;&#171;&#189; 18), 5.8 &#226;&#171;&#187; 107 (n &#226;&#171;&#189; 19), 4.3 &#226;&#171;&#187; 108 (n &#226;&#171;&#189; 18) <br /> performed BLAST analysis nonredundant GenBank sequences. <br />                                                                                       CFU. deaths occurred 24 48 h challenge <br />    Statistical analyses. Data presented means &#226;&#171;&#190; standard errors means. P values 0.05/n (n &#226;&#171;&#189; number comparisons) considered statisti-        3.5 &#226;&#171;&#187; 108 (n &#226;&#171;&#189; 19) 7.7 &#226;&#171;&#187; 109 (n &#226;&#171;&#189; 18) CFU, respec- <br /> cally significant based Bonferroni correction multiple comparisons,        tively. trend increased survival rats chal- P values &#226;&#172;&#381;0.05/n &#226;&#172;?0.05 considered representing trend. vivo     lenged 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU compared rats vitro data shown normally distributed Kolmogorov-            challenged 7.7 &#226;&#171;&#187; 109 CFU (P &#226;&#171;&#189; 0.03). data support <br /> Smirnov normality test (P &#226;&#172;&#381; 0.10, alpha &#226;&#171;&#189; 0.05) (Prism 4 MacIntosh; Graph- <br /> Pad Software ) analyzed using tailed unpaired t log rank <br />                                                                                       contention  baumannii able cause lethal pul- <br /> tests.                                                                                monary infection rat pneumonia model                                                                                       dependent challenge inoculum.  growth/clear- <br />                                                                                       ance  &#226;&#8364;&#339;Bacterial growth/clearance&#226;&#8364;? , oxygenation, <br />                                   RESULTS <br />                                                                                       BALF albumin data  &#226;&#8364;&#339;Acute lung injury&#226;&#8364;?  sug- <br />   rat pneumonia model clinically relevant assessing                        gest death,  progressive bacterial <br /> Acinetobacter infection. Acinetobacter capable causing                     proliferation associated respiratory failure. <br />  3580      RUSSO ET AL.                                                                                                               INFECT. IMMUN. <br />  <br />  <br />  <br />  <br />   FIG. 3. Oxygenation concentration rats 3, 6, 24, 48, 72, 168 h post-challenge different titers  baumannii strain 307-0294. <br /> Rats given 7.0 &#226;&#171;&#187; 106, 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU 307-0294 intratracheal instillation, aortic blood obtained 3, 6, 24, 48, 72, 168 h determination PaO2/FiO2 (mm Hg). trend increased oxygenation 24 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU (&amp;, P &#226;&#171;&#189; 0.02 0.04, respectively). Data means &#226;&#171;&#190; standard <br /> errors means n &#226;&#171;&#189; 3 challenge titer time point. <br />  <br />  <br />  <br />    Acute lung injury. determine effect  baumannii                BALF albumin observed lowest challenge acute lung injury, arterial oxygenation (PaO2/FiO2 ratio)                 inocula (7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU) (Fig. 4). greatest BALF albumin measured 3, 6, 24, 48, 72, 168 h                increase BALF albumin occurred 24 h following challenge rats various titers 307-0294.                 highest 307-0294 challenge inocula (3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 challenge 307-0294, decreases oxygenation                  CFU) 6 h lowest challenge inocula (5.8 &#226;&#171;&#187; <br /> levels, reflect acute lung injury, similar               107 7.0 &#226;&#171;&#187; 106 CFU); levels decreased  pronounced highest challenge inocula (3.5 &#226;&#171;&#187; 108               significant decrease trend significant  7.7 &#226;&#171;&#187; 109 CFU). lesser effect oxygenation observed               crease concentration BALF albumin various times lowest challenge inocula (7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107               rats challenged 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU compared <br /> CFU) (Fig. 3). greatest decrease oxygenation occurred                 rats challenged 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU 24 h highest 307-0294 challenge inocula (3.5 &#226;&#171;&#187;              (Fig. 4). data demonstrated increase BALF <br /> 108 7.7 &#226;&#171;&#187; 109 CFU), 48 h highest challenge                albumin greatest  baumannii able grow <br /> inoculum (5.8 &#226;&#171;&#187; 107 CFU), 72 h lowest challenge               (e.g., 307-0294 challenge inocula 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 <br /> inoculum (7.0 &#226;&#171;&#187; 106 CFU). Levels recovered                CFU) compared  baumannii cleared (e.g., 307- baseline. trend increased oxygenation                0294 challenge inocula 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU). 24 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats                  Host inflammatory response. determine effect  <br /> challenged 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU (P &#226;&#171;&#189; 0.02                    baumannii pulmonary levels TNF-&#226;?&#163;, 1&#226;?&#164;, CINC-1 <br /> 0.04, respectively). data demonstrated  bau-               vivo, mediators assessed cell-free BALF su- <br /> mannii able grow (e.g., 307-0294 challenge inocula                 pernatants 3, 6, 24, 48, 72, 168 h following challenge 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU), decrease oxygenation                 rats various titers 307-0294. challenge 307- <br /> greatest occurred quickly  baumannii                    0294, levels TNF-&#226;?&#163;, 1&#226;?&#164;, CINC-1 barely mea- cleared (e.g., 307-0294 challenge inocula 7.0 &#226;&#171;&#187; 106               surable challenge inoculum 7.0 &#226;&#171;&#187; 106 CFU, increased <br /> 5.8 &#226;&#171;&#187; 107 CFU).                                                              challenge inoculum 5.7 &#226;&#171;&#187; 107 CFU,    Leakage albumin vasculature alveolar                 similar orders magnitude challenge inocula 3.5 &#226;&#171;&#187; <br /> spaces measure acute lung injury. challenge              108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU (Fig. 5A C). 307-0294, increases BALF albumin levels                     challenge 307-0294, TNF-&#226;?&#163; CINC-1 levels peaked similar pronounced highest challenge                 6 h essentially limit detection 72 h (Fig. <br /> inocula (3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU) lesser effect                  5A C), 1&#226;?&#164; levels peaked 24 h  VOL. 76, 2008                                                                                                 BAUMANNII BIOLOGY                3581 <br />  <br />  <br />  <br />  <br />    FIG. 4. BALF albumin concentration rats 3, 6, 24, 48, 72, 168 h post-challenge different titers  baumannii strain <br /> 307-0294. Rats given 7.0 &#226;&#171;&#187; 106, 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU 307-0294 intratracheal instillation, cell-free BALF obtained 3, 6, 24, 48, 72, 168 h deter- <br /> mination albumin. significant decrease concen- <br /> tration BALF albumin 24 h rats challenged 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 CFU (*, P &#226;&#171;&#189; <br /> 0.0008 0.002, respectively) 168 h rats challenged 7.0 &#226;&#171;&#187; <br /> 106 5.8 &#226;&#171;&#187; 107 CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 <br /> CFU (*, P &#226;&#171;&#189; 0.006 0.008, respectively). trend decrease concentration BALF albumin 6 h rats chal- <br /> lenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 4.3 &#226;&#171;&#187; 108 <br /> CFU (&amp;, P &#226;&#171;&#189; 0.03), 24 h rats challenged 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; <br /> 107 CFU compared rats challenged 7.7 &#226;&#171;&#187; 109 CFU (&amp;, P &#226;&#171;&#189; 0.01 0.02, respectively), 168 h rats challenged 7.0 &#226;&#171;&#187; 106 <br /> CFU compared rats challenged 4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.01). <br /> Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 3 challenge titer time point. <br />  <br />  <br />  <br /> limit detection 72 h (Fig. 5B). significant <br /> decrease trend significant decrease TNF-&#226;?&#163;,                       FIG. 5. TNF-&#226;?&#163;, 1&#226;?&#164;, CINC-1 cell-free BALF concentrations 1-&#226;?&#164;, CINC-1 levels various times rats challenged                rats 3, 6, 24, 48, 72, 168 h post-challenge different 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU compared rats challenged                 titers  baumannii strain 307-0294.   TNF-&#226;?&#163;. (B) 1&#226;?&#164;. <br />                                                                              (C) CINC-1. Rats given 7.0 &#226;&#171;&#187; 106, 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU (Fig. 5).                 7.7 &#226;&#171;&#187; 109 CFU 307-0294 (blood isolate, ST15, clonal group 1) <br /> data demonstrated challenge 307-0294 levels               intratracheal instillation, BALF obtained determination <br /> TNF-&#226;?&#163;, 1&#226;?&#164;, CINC-1 increased increasing chal-                     cytokine/chemokine levels 3, 6, 24, 48, 72, 168 h.   lenge inocula 7.0 &#226;&#171;&#187; 106 3.5 &#226;&#171;&#187; 108 CFU reached                    significant decrease TNF-&#226;?&#163; levels 6 h rats challenged plateau levels   levels early proin-             7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 4.3 &#226;&#171;&#187; 108 CFU (*, P &#226;&#171;&#189; <br />                                                                              0.01) trend decreased TNF-&#226;?&#163; levels 3 h rats challenged <br /> flammatory cytokines decreased 6 h TNF-&#226;?&#163;                       7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 7.7 &#226;&#171;&#187; 109 CFU <br /> CINC-1 24 h 1&#226;?&#164;. data support                      (&amp;, P &#226;&#171;&#189; 0.049), 6 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared <br /> contention magnitude challenge inoculum               rats challenged 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU (&amp;, P &#226;&#171;&#189; 0.02), dominant factor affecting levels TNF-&#226;?&#163;, 1&#226;?&#164;, CINC-1.                6 h rats challenged 5.8 &#226;&#171;&#187; 107 CFU compared rats challenged <br />                                                                              4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.04), 24 h rats challenged    Pulmonary neutrophils present BALF assessed                  7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; challenge various titers 307-0294               0.04). (B) trend decreased 1&#226;?&#164; levels 24 h rats <br /> 7.7 &#226;&#171;&#187; 109 CFU challenge inoculum). Neutrophil counts peaked                  challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 3.5 &#226;&#171;&#187; 6 h decreased (Fig. 6). total numbers               108 CFU (&amp;, P &#226;&#171;&#189; 0.04). (C) significant decrease CINC-1 <br /> neutrophils similar challenge titers 307-             levels 3 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats <br />                                                                              challenged 7.7 &#226;&#171;&#187; 109 CFU (*, P &#226;&#171;&#189; 0.007) 6 h rats <br /> 0294, challenge lowest titer (7.0 &#226;&#171;&#187; 106                challenged 7.0 &#226;&#171;&#187; 106 compared rats challenged 3.5 &#226;&#171;&#187; 108, <br /> CFU) 24, 48, 72, 168 h, significant                 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU (*, P &#226;&#171;&#189; 0.004, 0.0003, 0.004, <br /> decrease trend significant decrease num-                respectively) rats challenged 5.8 &#226;&#171;&#187; 107 CFU compared ber neutrophils compared rats challenged                 rats challenged 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU (*, P &#226;&#171;&#189; <br />                                                                              0.007, 0.0006, 0.008, respectively). Data means &#226;&#171;&#190; standard <br /> 5.7 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108 CFU (Fig. 6). timing                 errors means n &#226;&#171;&#189; 3 challenge titer time point. maximal neutrophil counts corresponded timing maximal TNF-&#226;?&#163; CINC-1 levels, unlike cytokines, neu- <br /> trophil counts decreased slowly persisted 168 h.                lenge Acinetobacter. supports hypothesis  maximal neutrophil response seen                  immunocompetent rat pneumonia model clinically relevant lowest 307-0294 challenge titers.                                        assessing  baumannii infection. <br />    Taken  data demonstrate bacterial                       rat soft-tissue infection model clinically relevant growth, acute lung injury, appropriate host inflamma-                 assessing Acinetobacter infection. Surgical sites, ulcers, tory response occur rat pneumonia model chal-                   patients sustained traumatic (e.g., battlefield)  <br />  3582      RUSSO ET AL.                                                                                                              INFECT. IMMUN. <br />  <br />  <br />  <br />  <br />    FIG. 6. Neutrophil numbers BALF rats 3, 6, 24, 48, 72, 168 h post-challenge different titers  baumannii strain 307-0294. <br /> Rats given 7.0 &#226;&#171;&#187; 106, 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU 307-0294 intratracheal instillation; BALF collected 3, 6, 24, 48, 72, 168 h; cells harvested BALF enumerated Coulter counting. Neutrophil numbers based leukocyte differentials obtained stained cytoslides (Materials Methods). Cell counts animals challenged 7.7 &#226;&#171;&#187; <br /> 109 CFU. significant decrease number neutrophils 72 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 4.3 &#226;&#171;&#187; 108 CFU (*, P &#226;&#171;&#189; 0.0003) trend decrease number neutrophils 24 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 5.7 &#226;&#171;&#187; 107 4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.019 0.041, respectively), 48 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU <br /> compared rats challenged 3.5 &#226;&#171;&#187; 108 4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.025 0.019, respectively), 72 h rats challenged 7.0 &#226;&#171;&#187; 106 <br /> CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.037), 168 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 5.7 &#226;&#171;&#187; 107 4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.022 0.022, respectively). Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 3 challenge <br /> titer time point. <br />  <br />  <br /> juries risk soft-tissue infection Acin-              mined), 979 (OIFC327) (environmental isolate, ST24, <br /> etobacter (30, 48).  tested hypothesis                 clonal group undetermined) compared 307- immunocompetent rat soft-tissue infection model clin-                 0294 model. patterns observed: growth <br /> ically relevant assessing  baumannii infection. brief,              (979), clearance (853), variable degree clearance subcutaneous fluid-filled space created                  3 6 h followed different rates growth (855 &#226;&#172;&#381; 307-0294 &#226;&#172;&#381; <br /> oculated bacterial strain assessed, samples                   900) (Fig. 7). significant decrease trend withdrawn, bacterial titers measured                  significant decrease survival 853 900 various <br /> time  7 days). growth 307-0294                       times compared 307-0294, 855, 979. model assessed 48 h (Fig. 7). Clearance observed                 quite sensitive differentiating abilities different  6 h, followed growth achievement plateau                     baumannii strains survive vivo. Interestingly, density 24 h. ability 307-0294 survive host&#226;&#8364;&#8482;s               number strains assessed small, predict defenses proliferate soft-tissue environment                 survival blood isolates 307-0294 853 consistent ability cause soft-tissue infection             greatest, case. data support humans. data support hypothesis model                    hypothesis model used discriminate clinically relevant used study Acinetobacter                inherent differences virulence various  baumannii setting.                                                             clinical isolates. <br />    rat soft-tissue infection model used assess                Serum sensitivity Acinetobacter isolates vitro correlates <br /> relative virulence various  baumannii clinical isolates.                growth soft-tissue infection model. Comple- tested hypothesis soft-tissue infection                 ment neutrophils innate host defense factors known <br /> model used discriminate inherent                     active soft-tissue infection model (7, 8). differences virulence various  baumannii clinical iso-               various strains Acinetobacter variably cleared lates. growth 853 (OIFC031) (blood isolate, ST11,                     model, hypothesized complement important <br /> clonal group II), 855 (axillary isolate, ST14, clonal group                  host factor protecting  baumannii infection III), 900 (perineal isolate, ST19, clonal group undeter-                     vivo.  serum sensitivity  baumannii <br />  VOL. 76, 2008                                                                                                BAUMANNII BIOLOGY               3583 <br />  <br />  <br />  <br />  <br />   FIG. 7. Growth/clearance  baumannii strains 307-0294, 853, 855, 900, 979 rat soft-tissue infection model. Rats prepared challenged bacterial strains assessed described Materials Methods. Bacterial titers determined 0, 3, 6, 24, 48 h. significant decrease trend significant decrease survival 853 900 various times compared 307-0294, 855, 979. Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 4 9. *, 853 compared 307-0294, P &#226;&#172;? 0.001 0.0005 3 6 h, <br /> respectively; *, 853 compared 855, P &#226;&#171;&#189; 0.0004 48 h; *, 853 compared 979, P &#226;&#171;&#189; 0.0005 0.003 24 48 h, respectively. #, 853 <br /> compared 307-0294, P &#226;&#171;&#189; 0.045 24 h; #, 853 compared 855, P &#226;&#171;&#189; 0.03 24 h; #, 853 compared 979, P &#226;&#171;&#189; 0.02 0.03 3 6 h, <br /> respectively; *, 900 compared 307-0294, P &#226;&#171;&#189; 0.007 24 h; *, 900 compared 855, P &#226;&#171;&#189; 0.004 &#226;&#172;?0.0001 24 48 h, respectively; *, 900 <br /> compared 979, P &#226;&#171;&#189; 0.002, 0.005, &#226;&#172;?0.0001, &#226;&#172;?0.0001 3, 6, 24, 48 h, respectively; #, 900 compared 307-0294, P &#226;&#171;&#189; 0.019 48 h. (Inset) <br /> Enlargement data 307-0294, 855, 979 0 6 h. trend significant difference growth 307-0294 855 compared 979. *, 855 compared 979, P &#226;&#171;&#189; 0.005; #, 307-0294 compared 979, P &#226;&#171;&#189; 0.02. <br />  <br />  <br />  <br />  <br /> strains 307-0294, 853, 855, 900, 979 assessed 3 h vitro (Fig. 8). strains grew similarly 90% serum heated 56&#194;&#176;C 30 min inactivate comple- <br /> ment-mediated killing LB medium (data shown). strains exposed 90% active serum, growth 307-0294, 855, 900 similar. contrast, <br /> 853 underwent approximate 2-log killing 900  <br /> went approximate 0.5-log killing followed recovery starting titer 3 h; differences significant <br /> compared 307-0294, 855, 979. data roughly <br />                                                                                FIG. 8. Effect 90% normal human serum viability correlate growth/clearance soft-tissue infection                 baumannii strains 307-0294, 853, 855, 900, 979 vitro. Assays <br /> model (Fig. 7).  soft-tissue infection model                performed described Materials Methods. strains discriminatory, 307-0294, 855, 979 demon-                     assessed presence 90% heat-inactivated (56&#194;&#176;C strating differing growth/clearance capabilities,                30 min) normal human serum, growth rates similar; serum sensitivity assay, survival capabilities 307-               data shown. survival 853 900                                                                             significantly decreased compared 307-0294, 855, 979. <br /> 0294, 855, 979 similar. surprising               Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 4 6. *, 853 <br /> multiple host defense factors (e.g., professional phagocytes                compared 307-0294, 855, 979. P &#226;&#172;?0.0001 comparisons antimicrobial peptides) addition complement                   853 307-0294 979. P &#226;&#172;?0.0001, 0.0006, 0.002 present soft-tissue infection model. Nonetheless,                    853 compared 855 1, 2, 3 h, respectively. #, 900 compared <br />                                                                             307-0294, 855, 979. P &#226;&#172;? 0.0001, 0.0006, &#226;&#172;?0.0001 900 data support hypothesis complement                    compared 307-0294; P &#226;&#171;&#189; 0.002, 0.008, 0.009 900 compared <br /> host defense factor contributes clearance                  855; P &#226;&#171;&#189; 0.0004, &#226;&#172;?0.0001, &#226;&#172;? 0.0001 900 compared 979 baumannii vivo.                                                          1, 2, 3 h, respectively. <br />  3584     RUSSO ET AL.                                                                                                        INFECT. IMMUN. <br />  <br />  <br />                                                                          ratory previously used studies extraintestinal patho- <br />                                                                          genic E. coli clinically relevant assessing  baumannii <br />                                                                          (37, 41, 42). lung important site Acinetobacter <br />                                                                          infection humans, challenge  baumannii, <br />                                                                          pneumonia model demonstrated features  <br />                                                                          fection critical clinically relevant model:  <br />                                                                          bacterial growth/clearance, ensuing host inflammatory  <br />                                                                          sponse, acute lung injury, death respiratory failure <br />                                                                          following progressive bacterial proliferation (Fig. 1 6). Soft <br />                                                                          tissue increasingly recognized important site                                                                          Acinetobacter infection battlefield injuries, surgical sites,   FIG. 9. Growth/clearance  baumannii strain 307-0294 mutant derivative 307.5 rat soft-tissue infection model. Rats     ulcers (5, 11, 18). able demonstrate growth prepared challenged bacterial strains assessed   307-0294 soft-tissue infection model, occurs soft- described Materials Methods. Bacterial titers deter-      tissue infection, supporting hypothesis. mined 0, 3, 6, 24, 48 h.                                          hypothesized soft-tissue infection model used <br />                                                                          discriminate inherent levels virulence pos- <br />                                                                          sessed various Acinetobacter strains. support  var- <br />    rat soft-tissue infection model used efficiently        ious patterns growth observed Acinetobacter <br /> assess gene essentiality vivo. safe reliable agents           strains tested (Fig. 7). scope predictable activity  baumannii presently             report, biologic data used conjunction nonexistent, need identify new antimicrobial tar-          molecular epidemiologic data means predicting gets Acinetobacter. multiple approaches accom-            virulence Acinetobacter isolates. Given variable growth <br /> plish goal exist, starting point strategy           Acinetobacter strains soft-tissue infection model identify Acinetobacter genes essential growth. rat soft-         fact complement active host defense factor tissue infection model efficient model assessing vivo       site, hypothesized complement important host <br /> growth/survival multiple samples obtained                 factor protecting  baumannii infection vivo. single animal time.  hypothesized               Growth/clearance  baumannii strains soft-tissue soft-tissue infection model serve effective         infection model roughly correlated growth/clearance screening tool establishing gene essentiality drug dis-          vitro serum sensitivity studies (Fig. 8), supporting covery. randomly mutagenized 307-0294 using trans-                hypothesis. Lastly, supported hypothesis soft- <br /> poson EZ-Tn5&#226;&#172;?kan-2&#226;&#172;&#381;. Mutants isolated MH plates                   tissue infection model used establish essenti- <br /> taining kanamycin subsequently gridded ascites                 ality Acinetobacter genes vivo, important characteristic <br /> plates supplemented kanamycin. Chromosomal sequenc-                 potential drug targets (Fig. 9). did utilize <br /> ing (using primers ends EZ-Tn5&#226;&#172;?kan-2&#226;&#172;&#381;)                   models assess vaccine candidates virulence factors, <br /> performed mutants displayed minimal growth              self-evident used purpose  <br /> ascites plates, enabling localization transposon              models described report certain advantages <br /> sertion. mutants (307.5) contains transposon              previously described Acinetobacter animal infection <br /> insertion gene codes phosphoribosylaminoimid-            models (4, 21, 22, 25&#226;&#8364;&#8220;27, 31, 36).  critical able <br /> azole-succinocarboxamide synthase. Quantitative growth curves            bacterial growth significant period time performed LB medium demonstrated differ-            pneumonia model. rat model, highest challenge <br /> ence growth 307-0294 307.5 (data                      inocula able demonstrate growth 24 48 h <br /> shown). test hypothesis soft-tissue infection            post-bacterial challenge (Fig. 1).  highest chal- <br /> model used establish gene essentiality vivo,           lenge inocula rats succumbed infection (Fig. 2). Given <br /> assessed growth AB307.5 model (Fig. 9). 307.5,            challenge inocula significant acute lung injury mutant derivative 307-0294, cleared, sup-               occurred (Fig. 3 4), reasonable infer porting hypothesis.                                                  animals died respiratory insufficiency  opposed &#226;&#8364;&#339;cy- <br />                                                                          tokine storm&#226;&#8364;?). did perform blood cultures                           DISCUSSION                                     animals, exclude possibility concomitant <br />                                                                          bacteremia, contribute mortality    Acinetobacter pathogen increasing medical impor-              setting.  bacteremia did occur ani- <br /> tance (13, 14, 19, 33). Little known mechanisms          mals, bacteremia occurs severe pneumonia humans <br /> pathogenesis, vaccine candidates identified,           result does make model relevant. Taken increasing proportion strains highly resistant            data support model particularly <br /> timicrobials (29, 32). availability clinically relevant        relevant studying aspects Acinetobacter pneumonia: <br /> imal infection models facilitate studies innate vir-          bacterial growth/clearance, acute lung injury, ulence various Acinetobacter clinical isolates, potential             host response. contrast, bacteria cleared murine <br /> virulence factors, vaccine candidates, drug targets vivo          pneumonia models.  majority Acinetobacter used pharmacokinetic chemotherapeutic                 murine pneumonia models reported date, animals <br /> investigations. report tested hypotheses         received porcine mucin bacterial challenge (4, 25, 26, <br /> rat pneumonia soft-tissue infection models labo-            34, 36) rendered neutropenic (20, 21), permutations <br />  VOL. 76, 2008                                                                                                             BAUMANNII BIOLOGY                     3585 <br />  <br />  present patients develop Acineto-                          4. Bernabeu-Wittel, M., C. Pichardo,  Garcia-Curiel, M. E. Pachon-Ibanez, <br />                                                                                        J. Ibanez-Martinez, M. E. Jimenez-Mejias, J. Pachon. 2005. Pharma- <br /> bacter pneumonia. report used murine model,                              cokinetic/pharmacodynamic assessment vivo efficacy imipenem <br /> Acinetobacter grew 4 h underwent significant                        combination amikacin treatment experimental <br /> clearance 24 h (22). major advantage soft-tissue                           multiresistant Acinetobacter baumannii pneumonia. Clin. Microbiol. Infect. <br />                                                                                        11:319&#226;&#8364;&#8220;325. <br /> infection model multiple sampling performed                          5. Centers Disease Control Prevention. 2004. Acinetobacter baumannii time animal, making time cost efficient                        infections patients military medical facilities treating injured U.S. <br /> initial assessment strains vivo. contrast, pneu-                       service members, 2002&#226;&#8364;&#8220;2004. MMWR Morb. Mortal. Wkly. Rep. 53:1063&#226;&#8364;&#8220; <br />                                                                                        1066. <br /> monia models thigh infection model (27) animals need                         6. Chen, M. , P. R. Hsueh, L. N. Lee, C. J. Yu, P. C. Yang, K. T. Luh. euthanized measurement bacterial growth/clearance,                           2001. Severe community-acquired pneumonia Acinetobacter bauman- <br /> injury, host response.  thigh infection                         nii. Chest 120:1072&#226;&#8364;&#8220;1077. <br />                                                                                     7. Dalhoff, , G. Frank, G. Luckhaus. 1982. granuloma pouch: model animals rendered neutropenic (27).                             vivo model pharmacokinetic chemotherapeutic investigations.  Bio- <br /> lungs soft tissue clearly different host environments                          <span id='am-1' about='obo:IMR_0000947' typeof='owl:Thing obo:IMR_0000001'><span id='am-2' property="rdfs:label" content="chemical" datatype="xsd:string"></span><span id='am-3' property="oboInOwl:id" content="IMR:0000947" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>chemical</span> histological characterization. Infection 10:354&#226;&#8364;&#8220;360. contain different growth host defense factors, clinical                    8. Dalhoff, , G. Frank, G. Luckhaus. 1983. granuloma pouch:                                                                                        vivo model pharmacokinetic chemotherapeutic investigations. II. <br /> isolates mutant derivatives 307-0294 cleared                          Microbiological characterization. Infection 11:41&#226;&#8364;&#8220;46. soft-tissue infection model cleared                        9. Davidson, B., P. Knight, J. Helinski, N. Nader, T. Shanley, K. Johnson. <br />                                                                                        1999. role tumor necrosis factor-alpha pathogenesis aspira- <br /> sessed pneumonia model (data shown).                            tion pneumonitis rats. Anesthesiology 91:486&#226;&#8364;&#8220;499. <br /> did measure host response  baumannii studies,                     10. Davis, K. , K.  Moran, C. K. McAllister, P. J. Gray. 2005. Multidrug- soft-tissue infection model previously                      resistant Acinetobacter extremity infections soldiers. Emerg. Infect. Dis. <br />                                                                                        11:1218&#226;&#8364;&#8220;1224. <br /> reported (7, 8).  soft-tissue infection model                     11. Department Veterans Affairs. 2004. Update Colleagues&#226;&#8364;&#8482; Letter sent cost-effective high throughput answering certain                          April 23, 2004 concerning Acinetobacter baumannii. Department Veterans <br /> biologic questions. appear model                           Affairs, Veterans Health Administration, Washington, DC. <br />                                                                                    12. Ecker, J. , C. Massire, T.  Hall, R. Ranken, T. T. Pennella, C.  Ivy, L. B. <br /> used initial, efficient means assess growth/clear-                       Blyn, S.  Hofstadler, T. P. Endy, P. T. Scott, L. Lindler, T. Hamilton, C. <br /> ance Acinetobacter vivo.                                                         Gaddy, K. Snow, M. Pe, J. Fishbain, D. Craft, G. Deye, S. Riddell, E. <br />    main goal report, interesting                       Milstrey, B. Petruccelli, S. Brisse, V. Harpin,  Schink, D. J. Ecker, R. <br />                                                                                        Sampath, M. W. Eshoo. 2006. Identification Acinetobacter species aspects  baumannii biology illuminated                           genotyping Acinetobacter baumannii multilocus PCR mass spec- <br /> study. soft-tissue infection model discriminating                         trometry. J. Clin. Microbiol. 44:2921&#226;&#8364;&#8220;2932. growth differences strains vitro serum                     13. Falagas, M. E., E.  Karveli. 2007. changing global epidemiology <br />                                                                                        Acinetobacter baumannii infections: development major public <br /> sensitivity testing (Fig. 7 8). surprising                    health implications. Clin. Microbiol. Infect. 13:117&#226;&#8364;&#8220;119. soft-tissue infection model host factors critical protect-                  14. Fournier, P. E., H. Richet. 2006. epidemiology control ing extracellular bacterial pathogens like Acinetobacter                       Acinetobacter baumannii health care facilities. Clin. Infect. Dis. 42:692&#226;&#8364;&#8220; <br />                                                                                        699. present including complement, antimicrobial peptides,                      15. Garzoni, C., S. Emonet, L. Legout, R. Benedict, P. Hoffmeyer, L. Bernard, <br /> professional phagocytes. Second,  baumannii strains 307-                             J. Garbino. 2005. Atypical infections tsunami survivors. Emerg.  <br />                                                                                        fect. Dis. 11:1591&#226;&#8364;&#8220;1593. <br /> 0294 853 blood isolates displayed diamet-                        16. Gaynes, R., J. R. Edwards. 2005. Overview nosocomial infections <br /> rically opposed growth/clearance patterns vivo. data                          caused gram-negative bacilli. Clin. Infect. Dis. 41:848&#226;&#8364;&#8220;854. <br /> highlight fact innate virulence clinical isolates                  17. Jain, R., L. H. Danziger. 2004. Multidrug-resistant Acinetobacter infec- <br />                                                                                        tions: emerging challenge clinicians. Ann. Pharmacother 38:1449&#226;&#8364;&#8220;1459. necessarily predicted site isolation.                             18. Johnson, E. N., T. C. Burns, R.  Hayda, D. R. Hospenthal, C. K. <br />    summary, supported hypotheses utility                         Murray. 2007. Infectious complications open type III tibial fractures rat pneumonia soft-tissue infection models studying                         combat casualties. Clin. Infect. Dis. 45:409&#226;&#8364;&#8220;415. <br />                                                                                    19. Joly-Guillou, M. L. 2005. Clinical impact pathogenicity Acineto- <br /> Acinetobacter biology. models described                            bacter. Clin. Microbiol. Infect. 11:868&#226;&#8364;&#8220;873. <br /> report clinically relevant possess certain advantages                      20. Joly-Guillou, M. L., M. Wolff, R. Farinotti,  Bryskier, C. Carbon. 2000. previously described models. models used                          vivo activity levofloxacin combination imipenem                                                                                        amikacin mouse model Acinetobacter baumannii pneumonia. J.  <br /> study innate virulence various Acinetobacter clinical iso-                      timicrob. Chemother. 46:827&#226;&#8364;&#8220;830. <br /> lates assess potential virulence factors, vaccine candi-                    21. Joly-Guillou, M. L., M. Wolff, J. J. Pocidalo, F. Walker, C. Carbon. 1997. <br /> dates, drug targets vivo used pharmaco-                          Use new mouse model Acinetobacter baumannii pneumonia eval- <br />                                                                                        uate postantibiotic effect imipenem. Antimicrob. Agents Chemother. <br /> kinetic chemotherapeutic investigations.                                           41:345&#226;&#8364;&#8220;351. <br />                                                                                    22. Knapp, S., C. W. Wieland, S. Florquin, R. Pantophlet, L. Dijkshoorn, N. <br />                         ACKNOWLEDGMENTS                                                Tshimbalanga, S. Akira, T. van der Poll. 2006. Differential roles                                                                                        CD14 toll-like receptors 4 2 murine Acinetobacter pneumonia. <br />   gratefully acknowledge financial support VA Merit                         J. Respir. Crit. Care Med. 173:122&#226;&#8364;&#8220;129. <br /> Review Department Veterans Affairs (T R.)                   23. Landman, D., J. M. Quale, D. Mayorga,  Adedeji, K. Vangala, J. Ravis- <br /> Army Medical Research Acquisition Activity contract                              hankar, C. Flores, S. Brooks. 2002. Citywide clonal outbreak mul- <br />                                                                                        tiresistant Acinetobacter baumannii Pseudomonas aeruginosa Brooklyn, <br /> W81XWH-05-1-0627 (T R. C.).                                                    N.Y.: preantibiotic era returned. Arch. Intern. Med. 162:1515&#226;&#8364;&#8220;1520. <br />                                                                                    24. Maegele, M., S. Gregor, E. Steinhausen, B. Bouillon, M. M. Heiss, W. <br />                                REFERENCES                                              Perbix, F. Wappler, D. Rixen, J. Geisen, B. Berger-Schreck, R. Schwarz. <br /> 1. Anstey, N. M., B. J. Currie, M. Hassell, D. Palmer, B. Dwyer, H. Seifert.       2005. long-distance tertiary air transfer care tsunami victims: <br />    2002. Community-acquired bacteremic Acinetobacter pneumonia tropical             injury pattern microbiological psychological aspects. Crit. Care <br />    Australia caused diverse strains Acinetobacter baumannii, car-        Med. 33:1136&#226;&#8364;&#8220;1140. <br />    riage throat risk groups. J. Clin. Microbiol. 40:685&#226;&#8364;&#8220;686.          25. Montero, , J. Ariza, X. Corbella,  Domenech, C. Cabellos, J. Ayats, F. <br /> 2. Anstey, N. M., B. J. Currie, K. M. Withnall. 1992. Community-acquired           Tubau, C. Borraz, F. Gudiol. 2004. Antibiotic combinations    Acinetobacter pneumonia Northern Territory Australia. Clin.            infections caused carbapenem-resistant Acinetobacter baumannii    fect. Dis. 14:83&#226;&#8364;&#8220;91.                                                                mouse pneumonia model. J. Antimicrob. Chemother. 54:1085&#226;&#8364;&#8220;1091. <br /> 3. Bergogne-Berezin, E., K. J. Towner. 1996. Acinetobacter spp. noso-       26. Pachon-Ibanez, M. E., F. Fernandez-Cuenca, F. Docobo-Perez, J. Pachon, <br />    comial pathogens: microbiological, clinical, epidemiological features.           Pascual. 2006. Prevention rifampicin resistance Acinetobacter <br />    Clin. Microbiol. Rev. 9:148&#226;&#8364;&#8220;165.                                                    baumannii experimental pneumonia murine model, using rifampicin <br />  3586         RUSSO ET AL.                                                                                                                                 INFECT. IMMUN. <br />  <br />       associated imipenem sulbactam. J. Antimicrob. Chemother. 58:689&#226;&#8364;&#8220;                model gram-negative bacterial pneumonia.  J. Physiol. Lung Cell. <br />       692.                                                                                    Mol. Physiol. 283:L655&#226;&#8364;&#8220;L663. <br /> 27.   Pantopoulou, , E. J. Giamarellos-Bourboulis, M. Raftogannis, T. Tsaga-          40.   Russo, T. , B.  Davidson, J. M. Beanan, R. Olson, B.  Holm, R. H. <br />       nos,  Dontas, P. Koutoukas, F. Baziaka, H. Giamarellou, D. Perrea.                Notter, P. R. Knight III. 2007. Capsule O-antigen extraint- <br />       2007. Colistin offers prolonged survival experimental infection multi-            estinal isolate Escherichia coli modulate cytokine levels rat macro- <br />       drug-resistant Acinetobacter baumannii: significance administration           phages vitro rat model pneumonia. Exp. Lung Res. 33:337&#226;&#8364;&#8220;356. <br />       rifampicin. Int. J. Antimicrob. Agents 29:51&#226;&#8364;&#8220;55.                               41.   Russo, T. , B.  Davidson, U. B. Carlino-MacDonald, J. D. Helinski, R. L. <br /> 28.   Paterson, D. L., Y. Doi. 2007. step closer extreme drug resistance             Priore, P. R. Knight III. 2003. effects Escherichia coli capsule, <br />       (XDR) gram-negative bacilli. Clin. Infect. Dis. 45:1179&#226;&#8364;&#8220;1181.                        O-antigen, host neutrophils, complement rat model Gram- <br /> 29.   Perez, F.,  M. Hujer, K. M. Hujer, B. K. Decker, P. N.  R.               negative pneumonia. FEMS Microbiol. Lett. 226:355&#226;&#8364;&#8220;361. <br />       Bonomo. 2007. Global challenge multidrug-resistant Acinetobacter bau-          42.   Russo, T. , B.  Davidson, S.  Genagon, N. M. Warholic, U. Macdonald, <br />       mannii. Antimicrob. Agents Chemother. 51:3471&#226;&#8364;&#8220;3484.                                     P. D. Pawlicki, J. M. Beanan, R. Olson, B.  Holm, P. R. Knight III. <br /> 30.   Petersen, K., M. S. Riddle, J. R. Danko, D. L. Blazes, R. Hayden, S.                  2005. E. coli virulence factor hemolysin induces neutrophil apoptosis       Tasker, J. R. Dunne. 2007. Trauma-related infections battlefield                 necrosis/lysis vitro necrosis/lysis lung injury rat pneumonia <br />       casualties Iraq. Ann. Surg. 245:803&#226;&#8364;&#8220;811.                                           model.  J. Physiol. Lung Cell. Mol. Physiol. 289:L207&#226;&#8364;&#8220;L216. <br /> 31.   Renckens, R., J. J. Roelofs, S. Knapp,  F. Vos, S. Florquin, T. van      43.   Russo, T. , M. C. Moffitt, C. H. Hammer, M. M. Frank. 1993. TnphoA- <br />       der Poll. 2006. acute-phase response serum amyloid inhibit                mediated disruption K54 capsular <span id='am-11' about='obo:IMR_0001790' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001'><span id='am-12' property="oboInOwl:id" content="IMR:0001790" datatype="xsd:string"></span><span id='am-13' property="rdfs:label" content="polysaccharide" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>polysaccharide</span> genes Escherichia coli <br />       inflammatory response Acinetobacter baumannii pneumonia. J. Infect. Dis.             confers serum sensitivity. Infect. Immun. 61:3578&#226;&#8364;&#8220;3582. <br />       193:187&#226;&#8364;&#8220;195.                                                                      44.   Scott, P., G. Deye,  Srinivasan, C. Murray, K. Moran, E. Hulten, J. <br />                                                                                               Fishbain, D. Craft, S. Riddell, L. Lindler, J. Mancuso, E. Milstrey, C. T. <br /> 32.   Rice, L. B. 2006. Challenges identifying new antimicrobial agents effective <br />                                                                                               Bautista, J. Patel,  Ewell, T. Hamilton, C. Gaddy, M. Tenney, G. Chris- <br />       treating infections Acinetobacter baumannii Pseudomonas <br />                                                                                               topher, K. Petersen, T. Endy, B. Petruccelli. 2007. outbreak       aeruginosa. Clin. Infect. Dis. 43:S100&#226;&#8364;&#8220;S105. <br />                                                                                               multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection <br /> 33.   Richet, H., P. E. Fournier. 2006. Nosocomial infections caused Acin- <br />                                                                                               military health care associated military operations       etobacter baumannii: major threat worldwide. Infect. Control Hosp. Epi- <br />                                                                                               Iraq. Clin. Infect. Dis. 44:1577&#226;&#8364;&#8220;1584. <br />       demiol. 27:645&#226;&#8364;&#8220;646. <br />                                                                                         45.   Sunenshine, R. H., M. O. Wright, L. L. Maragakis,  D. Harris, X. Song, <br /> 34.   Rodriguez-Hernandez, M. J., L. Cuberos, C. Pichardo, F. J. Caballero,                 J. Hebden, S. E. Cosgrove,  Anderson, J. Carnell, D. B. Jernigan, D. G. <br />       Moreno, M. E. Jimenez-Mejias,  Garcia-Curiel, J. Pachon. 2001.                    Kleinbaum, T. M. Perl, H. C. Standiford,  Sri <br /> </body></html>